Clinical Trial Update: Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

View source ↗

Summary

A clinical trial update reports vision improvement when wet age-related macular degeneration patients switch from Avastin and Macugen to Lucentis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Avastin (bevacizumab)
• Lucentis (ranibizumab)
• Macugen (pegaptanib sodium)

Snippet

Sponsor: Retina Institute of Hawaii | Conditions: Wet AMD | Status: COMPLETED